Invivyd (IVVD) Other Operating Expenses (2021 - 2026)
Invivyd's (IVVD) quarterly Other Operating Expenses came in at $1.3 million in Q2 2026, up 85.84% on a YoY basis from $685000.0 in Q2 2025, and up 11.67% quarter-over-quarter from $1.1 million in Q4 2025.
Analysis
Invivyd (IVVD) Other Operating Expenses (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Other Operating Expenses for 6 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Operating Expenses rose 85.84% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2026 stood at $4.2 million (up 37.29% YoY), and the FY2025 full-year result was $3.7 million, up 131.58% from the prior year.
- Other Operating Expenses advanced to $1.3 million in Q2 2026 per IVVD's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $17.8 million in Q4 2022 and bottomed at -$600000.0 in Q4 2023.
- Historically, Other Operating Expenses has averaged $2.4 million across 5 years, with a median of $829500.0 in 2023.
- The sharpest annual moves came in 2023 and 2025: Other Operating Expenses plunged 103.38% in 2023, then soared 678.41% in 2025.
- Over 5 years, Other Operating Expenses stood at $17.8 million in 2022, then slumped by 103.38% to -$600000.0 in 2023, then jumped by 220.67% to $724000.0 in 2024, then soared by 57.46% to $1.1 million in 2025, then climbed by 11.67% to $1.3 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $1.3 million, $1.1 million, and $1.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.27 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 685,000.00 |
| Mar 31, 2025 | 834,000.00 |
| Dec 31, 2024 | 724,000.00 |
| Sep 30, 2024 | 806,000.00 |
| Jun 30, 2024 | 88,000.00 |
| Dec 31, 2023 | -600,000.00 |
| Sep 30, 2023 | 4.60 Mn |
| Jun 30, 2023 | 150,000.00 |
| Mar 31, 2023 | 825,000.00 |
| Dec 31, 2022 | 17.77 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Sep 30, 2021 | 4.00 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 1.00 Mn |